Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pravastatin for Endothelial Injury in Pediatric BMT
NCT05524246Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pravastatin in endothelial injury, sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Clinically significant transaminitis at 35 days and Clinically significant renal dysfunction at 35 days. Started Jan 2023; status: completed.
02
Drugs
pravastatin
03
Conditions
endothelial injury
Beyond the preview
Go deeper on NCT05524246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524246.